EMA Shortens Regulatory Path For Antibacterials Against Multi-Resistant Pathogens
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Following new guidance from the European Medicines Agency, marketing approvals for antibacterials against multi-drug-resistant bugs could be granted in Europe on expanded Phase II clinical trial data, a path that multinational Roche is keen to explore.